ライフサイエンスコーパス: diagnostics

1 useful tool for benchmarking gene expression diagnostics.

2 entiate it from traditional laboratory-based diagnostics.

3 y providing a useful alternative to existing diagnostics.

4 56 684 children who had HCV testing by Quest Diagnostics.

5 food science, public health and safety, and diagnostics.

6 application as research and applied tools in diagnostics.

7 evelopment of new personalized therapies and diagnostics.

8 s advancing the field of infectious diseases diagnostics.

9 ology, and questions of molecular transplant diagnostics.

10 L-based devices in routine and point-of-care diagnostics.

11 y with the logic behind different structural diagnostics.

12 globulin assays that are commonly used in MM diagnostics.

13 ve recently become supplemented by molecular diagnostics.

14 e potential of engineered bacteria as living diagnostics.

15 th the introduction of vaccines and improved diagnostics.

16 s enormous potential for next-generation POC diagnostics.

17 applications in neutral atom lithography and diagnostics.

18 sequences is a major bottleneck in molecular diagnostics.

19 rized for application in point-of-care (POC) diagnostics.

20 roved the cost-effectiveness of tuberculosis diagnostics.

21 applications, especially infectious disease diagnostics.

22 have become a workhorse in routine clinical diagnostics.

23 opment of point-of-care devices to real-time diagnostics.

24 concentration levels and to support medical diagnostics.

25 s observations owing to the lack of adequate diagnostics.

26 ating this strategy for rapid, point-of-care diagnostics.

27 ensitive single-cell assay for early disease diagnostics.

28 DNA analyzer, with potential applications in diagnostics.

29 based treatment of acute AMR based on modern diagnostics.

30 nsing, distributed computing, and biomedical diagnostics.

31 d disassembly processes for therapeutics and diagnostics.

32 application of emerging technologies in POC diagnostics.

33 ble devices for point of care and home-based diagnostics.

34 es an alternative platform for point-of-care diagnostics.

35 ther the technology has application in virus diagnostics.

36 tness, and miniaturized point-of-care cancer diagnostics.

37 evalence of keratoconus in the modern era of diagnostics.

38 tation of rapid molecular infectious disease diagnostics.

39 re is a strong need for fast and noninvasive diagnostics.

40 uide therapy and, potentially, for molecular diagnostics.

41 evelopment of macromolecular therapeutics or diagnostics.

42 for the dissemination of diverse blood-based diagnostics.

43 were tested by immunodiffusion at MiraVista Diagnostics.

44 ntrast images needed for accurate, precision diagnostics.

45 that rely on enrichment, thereby expediting diagnostics.

46 ing a new wave of simple and rapid molecular diagnostics.

47 ly, and enhanced sensitivity molecular-level diagnostics.

48 nize many technologies, including biomedical diagnostics.

49 es, enzyme-based immunoassays, and microbead diagnostics.

50 challenges facing the development of new POC diagnostics.

51 g new biosensing technique for point-of-care diagnostics.

52 inical application and point-of-care medical diagnostics.

53 y to exploit the full potential of molecular diagnostics.

54 would have a great potential in the medical diagnostics.

55 ch is a critical attribute for point-of-care diagnostics.

56 werful method to perform efficient and early diagnostics.

57 f affinity biosensor technologies in medical diagnostics.

58 oped system is ready to be applicable to POC diagnostics.

59 d standardizing medical imaging and in vitro diagnostics.

60 red the performance of seven methods of bias diagnostics, all of which are based on the analysis of c

61 nsights on the recent advancements in cancer diagnostics, an extended table is incorporated, which in

62 s (HC), were analyzed via singleplex allergy diagnostics and a newly established immunoblot diagnosti

63 es represent essential tools in research and diagnostics and are rapidly growing in importance as the

64 g tremendous opportunities both for clinical diagnostics and as a research tool.

65 lytical chemistry, electrochemistry, medical diagnostics and bio-sensing.

66 with TB will require simpler, more sensitive diagnostics and broader strengthening of health systems.

67 inly attributable to more frequently applied diagnostics and demographic changes in our societies.

68 the ARLG's Leadership and Operations Center, Diagnostics and Devices Committee, and SDMC.

69 n lab-on-a-chip and microfluidic technology, diagnostics and drug delivery etc.

70 pipeline opens new avenues for early disease diagnostics and drug discovery.

71 he past decade has seen the emergence of new diagnostics and drugs for tuberculosis, a disease that k

72 this sensor is promising for use in clinical diagnostics and for biological and marine applications.

73 they are usually assessed through prediction diagnostics and goodness-of-fit tests.

74 and novel proteins, which may inform future diagnostics and immunotherapeutics for allergy to HDM.

75 mination to the YSD platform, and YSD brings diagnostics and inexpensive, facile protein-matrix gener

76 is a newer alternative for tuberculosis (TB) diagnostics and is capable of providing rapid drug resis

77 to a given analyte, is the gold standard in diagnostics and many biochemical techniques.

78 findings may be relevant for Abeta-directed diagnostics and may signify a role of SST14 in the etiol

79 Step 6 was to move beyond diagnostics and mechanistical risk assessment, towards p

80 , including the development of point-of-care diagnostics and microneedle patches, will facilitate pro

81 h in personalized medicine but also accurate diagnostics and monitoring drug therapies, which are cri

82 R), had a neurological examination, clinical diagnostics and multidisciplinary team review.

83 New applications for chromophores in diagnostics and operative treatment exploit unique chemi

84 biosensor an ideal choice for point of care diagnostics and personal healthcare systems.

85 t has shown many advantages in point-of-care diagnostics and personalized medicine.

86 y of biomedical processing steps for medical diagnostics and pharmaceutical purification.

87 ch and the development of improved molecular diagnostics and prevention schemes for this neglected pa

88 important biotechnological tool for clinical diagnostics and production of steroid drugs and insectic

89 be utilized as a valuable biomarker in early diagnostics and prognostication of these cancers.

90 h offer the potential for enabling precision diagnostics and prognostics, as well as targeted patient

91 ides exciting opportunities for non-invasive diagnostics and prognostics.

92 cancer illustrates the history of companion diagnostics and provides a lens through which to examine

93 sight into atherosclerotic lesion formation, diagnostics and response to therapy.

94 pe, which opens up new opportunities for POC diagnostics and sensing applications in resource-limited

95 reagents are widely used in basic research, diagnostics and separations and for clinical application

96 es the research and development of vaccines, diagnostics and therapeutics against influenza virus by

97 gation-prone proteins remain a challenge for diagnostics and therapeutics development.

98 n in mammals could facilitate improvement of diagnostics and therapeutics for affected patients with

99 lomics the potential to substantially affect diagnostics and therapeutics in cardiovascular medicine.

100 est an immunophenotype, toward new potential diagnostics and therapeutics to reduce risk, alleviate s

101 ssues is essential for insights into disease diagnostics and therapeutics, yet prediction of tissue-s

102 of data provides new opportunities to impact diagnostics and therapeutics.

103 hesize useful products or to serve as living diagnostics and therapeutics.

104 rlying AD is crucial to developing effective diagnostics and therapeutics.

105 ools to develop screens for anti-protofibril diagnostics and therapeutics.

106 ions in biofluids would be a breakthrough in diagnostics and therapeutics.

107 ate new opportunities for advances in cancer diagnostics and therapeutics.

108 rkers and the development of next-generation diagnostics and therapies for caries control.

109 ction of DNA and/or RNA is vital for disease diagnostics and to follow up alterations in gene express

110 ould in turn drive the development of better diagnostics and treatment approaches.

111 spects of precision medicine toward improved diagnostics and treatment development for these currentl

112 of rational guidelines for patient-specific diagnostics and treatment of RASopathies.

113 rns has major potential to advance molecular diagnostics and underpin research investigations.

114 tant advance with applications in flavivirus diagnostics and vaccine development.

115 including applications of advanced molecular diagnostics and vaccine probe studies, as well as a rene

116 s precise composite scores, accurate routine diagnostics, and applicability to next-generation clinic

117 ful reagents as the basis for glycan arrays, diagnostics, and carbohydrate-based vaccines.

118 tant in varied biological processes, disease diagnostics, and chemotherapeutic drug screening.

119 e need for further investment in alternative diagnostics, and considerations that should be made when

120 ransfusion, cellular therapy and blood-based diagnostics, and could significantly improve the sensiti

121 vestigate microbe-host interactions, perform diagnostics, and deliver therapeutics.

122 plications in areas such as medical science, diagnostics, and pharmacology.

123 and sensing, quantum communications, medical diagnostics, and so on.

124 tions focus on pathological and radiological diagnostics, and the main treatment modalities of surger

125 in optical data storage, document security, diagnostics, and therapeutics.

126 endous importance in cell signaling, medical diagnostics, and therapeutics.

127 n for the development of novel therapeutics, diagnostics, and vaccine candidates to combat diseases c

128 lopment of some new neglected disease drugs, diagnostics, and vaccines.

129 Diagnostics are a cornerstone of the practice of infecti

130 Accurate and timely diagnostics are critical for managing bacterial infectio

131 Diagnostics are crucial in mitigating the effect of dise

132 biomarker tests for active tuberculosis (TB) diagnostics are of the highest priority for global TB co

133 Point-of-care (POC) diagnostics are one of the quick and sensitive detection

134 Nucleic acid-based molecular diagnostics are particularly well suited for the rapid d

135 mendous advances in nanotechnology-empowered diagnostics are serving a substantial input to identify

136 New diagnostics are urgently needed to address emerging anti

137 Rapid diagnostics are urgently required given the large number

138 l Resistance Leadership Group has identified diagnostics as 1 of 4 major areas of emphasis.

139 ood-culture positivity, performance of rapid diagnostics as diagnostic surrogates, and better charact

140 cal detection methods are widely used in DNA diagnostics as it provide simple, accurate and inexpensi

141 r ZIKV progression, with rapid point-of-care diagnostics as the ultimate aim.

142 t novel approaches in clinical computational diagnostics as well as in therapy development against pr

143 In clinical diagnostics, as well as food and environmental safety pr

144 eaders provides accurate on-site and on-time diagnostics based on various types of chemical and biolo

145 cles (GNPs) are of considerable interest for diagnostics because of their simplicity and low-cost.

146 ding spatiotemporal targeting, environmental diagnostics, better molluscicides, new technologies (e.g

147 many fields including food safety, clinical diagnostics, biosafety and biosecurity.

148 the international unit (IU) using the Exact Diagnostics BKV verification panel, a secondary standard

149 esigned to help evaluate new rapid molecular diagnostics by developing, testing, and applying a MASTE

150 Neural circuit diagnostics-by which we mean identifying the locations a

151 pact of respiration on flow is necessary for diagnostics; (c) cardiopulmonary imaging, where cardiova

152 Rapid and accurate influenza diagnostics can improve patient care.

153 Sensitive and accurate diagnostics can play a pivotal role in achieving disease

154 Such diagnostics can substantially reduce the development tim

155 The current gold standard, culture-based diagnostics, can provide clinicians with comprehensive d

156 hese challenges, the importance and value of diagnostics cannot be underestimated.

157 Preclinical multiparametric diagnostics could help discover clinically relevant biom

158 Microarray-based component-resolved diagnostics (CRD) has become an accepted tool to detect

159 vel avenues in biosensing for fast screening diagnostics, decentralized monitoring and design of futu

160 or the developing world, point-of-care (POC) diagnostics design must account for limited funds, modes

161 The component-resolved diagnostics disclosed also a high heterogeneity at molec

162 ue, we discuss existing approaches to dengue diagnostics, disease prognosis, surveillance, and vector

163 The three diagnostics do not show significant differences in overa

164 y and disease, and paves the way to improved diagnostics, drug development, and drug delivery.

165 as defined the need for affordable products (diagnostics, drugs and insecticides).

166 great interest as potential therapeutics and diagnostics due to ease and robustness of programming th

167 here were few significant differences in any diagnostics due to pathogen type.

168 Histopathology and molecular diagnostics (e.g., 16S rRNA gene PCR/sequencing, Tropher

169 -reactive probes for biomedical research and diagnostics, emphasizing the needs and opportunities tha

170 Molecular diagnostics enable sensitive detection of respiratory vi

171 ole of DNA detection in the areas of disease diagnostics, environment monitoring and food safety.

172 ical, biotechnological, clinical and medical diagnostics, environmental and health monitoring, and fo

173 miniaturised bedside biosensors for clinical diagnostics exploiting MIR spectroscopy, to replace labo

174 Individual omics-wide molecular diagnostics, extracorporeal therapies, and drug developm

175 Paper-based microfluidic diagnostics first emerged in 2007 as a low-cost alternat

176 In most other domains, diagnostics focus on narrowly defined questions, provide

177 roved LFA holds great potential for diseases diagnostics, food safety control and environment monitor

178 diverse environmental, bio-defence, clinical diagnostics, food safety, water and security application

179 markers, and could be adapted to provide POC diagnostics for a range of pathogens.

180 mising technology enabling dynamic and rapid diagnostics for antimicrobial drug development and AMR d

181 esis and the development of therapeutics and diagnostics for Huntington's disease.

182 While the need for more sensitive diagnostics for intestinal helminths is well known, the

183 ine the advances in paper-based microfluidic diagnostics for medical diagnosis in the context of glob

184 linical applications including rapid mucosal diagnostics for microbiology, immune responses, and bioc

185 technology, we show the ability of tableted diagnostics for screening hepatitis B-positive patient s

186 er signature may improve risk prediction and diagnostics for the management of cardiovascular disease

187 Current multiplexed diagnostics for Zika, dengue, and chikungunya viruses ar

188 dvances in blood culture techniques, and new diagnostics guide the application of laboratory testing

189 ticle applications in laser therapeutics and diagnostics has brought about the need for establishing

190 the past decade, the principle of companion diagnostics has gained increasing purchase among laborat

191 Molecular diagnostics has generated substantial dividends in disse

192 The interest in DNA-protein-based diagnostics has recently been growing enormously, which

193 Rapid molecular diagnostics have great potential to limit the spread of

194 Recently, emerging molecular diagnostics have met requirements for speed, low cost, a

195 RATIONALE: Point-of-care (POC) diagnostics have the potential to reduce pretreatment lo

196 stem (NNDSS) from 2006 to 2014 and the Quest Diagnostics Health Trends national database from 2011 to

197 enges to development and evaluation of novel diagnostics in an emergency setting and suggestions for

198 om all 37 laboratories performing meningitis diagnostics in Botswana were collected from the period 2

199 , since tissue slices are routinely used for diagnostics in clinical settings, LESA-MS is ideally pla

200 e goal of improving accessibility to medical diagnostics in developing countries.

201 relative merits of 3 approaches to molecular diagnostics in hematologic malignancies: indication-spec

202 tection; however, a novel concept to improve diagnostics in infectious diseases relies instead on the

203 a comprehensive assessment of PZA molecular diagnostics in M/XDR TB cases.

204 lities in developed countries as well as POC diagnostics in resource-poor and developing countries.

205 g the cost-effectiveness of new tuberculosis diagnostics in South Africa.

206 delays all contribute to a need for improved diagnostics in the field of infectious diseases.

207 tment strategy by combining therapeutics and diagnostics in the same agent.

208 inappropriate markers for differential sIgE diagnostics in vespid venom allergy.

209 ar biology-based assay, developed by GenMark Diagnostics, Inc.

210 s for phenotype driven genomic discovery and diagnostics, integration of cross-species mapping effort

211 leic acid biomarkers for point-of-care (POC) diagnostics is currently limited by technical complexity

212 nges, but emerging use of component-resolved diagnostics is improving diagnostic accuracy.

213 translating biomarker candidates to clinical diagnostics is less pronounced.

214 Molecular diagnostics is typically outsourced to well-equipped cen

215 a modern approach combining therapeutics and diagnostics, is among the most promising concepts in nuc

216 r Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND) initiative for evaluation of mu

217 Genetic diagnostics may be advantageous in adults with chronic k

218 to biomarker discovery or histopathological diagnostics, more sensitive and in-depth profiling from

219 In contrast, infectious diseases diagnostics must contend with scores of potential pathog

220 ay an important role in the surveillance and diagnostics of blood-borne viruses.

221 ical diagnosis and can improve point-of-care diagnostics of dengue infection.

222 most commonly used technology for molecular diagnostics of genomic disorders.

223 present excellent advantages for miRNA-based diagnostics of human diseases.

224 abels, as well as three-dimensional handheld diagnostics of human subjects.

225 For noninvasive diagnostics of hypoxia, we propose the nonenzymatic sens

226 ate and sensitive alternatives for molecular diagnostics of MDR- and XDR-TB.

227 d aggressive disease is a major challenge in diagnostics of prostate cancer.

228 The clinical management and diagnostics of such patients requires an interdisciplina

229 preferential condensation makes them useful diagnostics of the hydrological cycle.

230 While diagnostics of these properties exist, they are often in

231 Molecular diagnostics offer an increase in sensitivity for detecti

232 ide range of fields, including point-of-care diagnostics or cellular in vivo biosensing when using ul

233 Bacteria can be engineered to function as diagnostics or therapeutics in the mammalian gut but com

234 abels have excellent potential in biomedical diagnostics, particularly when high signal to noise and

235 his heterogeneity is important for precision diagnostics, personalized predictions, and recruitment o

236 the epigenome for the development of future diagnostics, preventive strategies, and therapy for card

237 For molecular diagnostics, primers were designed from the capsule locu

238 Point-of-care (POC) diagnostics provide rapid actionable information for pat

239 cancer treatments and, when used with other diagnostics, provides guidance for clinicians in choosin

240 The increasing needs of point-of-care diagnostics, quarantine of epidemic pathogens, and preve

241 it could be an expensive addition to cancer diagnostics, rather than an affordable alternative to si

242 ion, mass screening and treatment with novel diagnostics, reactive case detection, and other measures

243 ligence may also benefit the optimization of diagnostics readout of other liquid biopsy biosources.

244 Modern ebolavirus diagnostics rely primarily on quantitative reverse trans

245 Rapid diagnostics reporting antibiotic susceptibility may exte

246 imited signal-to-background ratio, molecular diagnostics requires molecular amplification of the targ

247 Regrouping patient care, diagnostics, research, and development, the University H

248 At present, rapid molecular diagnostics (RMDs) that can identify this phenotype are

249 a, this methodology identifies a very simple diagnostics rule-free of any tuning parameters and exhib

250 for this technology in fields such as health diagnostics, safety & security, and environment monitori

251 lmArray gastrointestinal (GI) panel (BioFire Diagnostics, Salt Lake City, UT) is a simple, sample-to-

252 ial computed tomography obtained for routine diagnostics (sensitivity: 72.5%) and previously reported

253 In response to a need for better sepsis diagnostics, several new gene expression classifiers hav

254 articularly katG p.Ser315Thr, into molecular diagnostics should enable targeted treatment of patients

255 that can be arranged to perform either rapid diagnostics (single vial) or the high-throughput (96-wel

256 Germantown, MD) and the Onclarity assay (BD Diagnostics, Sparks, MD).

257 measure l-lactate concentration for clinical diagnostics, sports medicine, and the food industry.

258 Additional novel diagnostics, such as basophil activation tests, determin

259 iols is of fundamental importance in medical diagnostics, such as measuring the contents of glucose i

260 utomated Beckman Coulter DxN Veris Molecular Diagnostics System (DxN Veris System) was evaluated at 1

261 tem is also known as the Veris MDx molecular diagnostics system and the Veris MDx system.).

262 The DxN Veris molecular diagnostics system is also known as the Veris MDx molecu

263 utomated Beckman Coulter DxN Veris molecular diagnostics system was evaluated at 10 European virology

264 ments in cloud-connected point-of-care (POC) diagnostics technologies are pushing the frontiers of PO

265 two novel semi quantitative methods of bias diagnostics that appear to be more robust and reliable t

266 ak led to an explosion in the development of diagnostics that could be performed at or near the point

267 Rapid diagnostics that enable identification of infectious age

268 Therefore, molecular diagnostics that include markers for rifampicin resistan

269 Molecular diagnostics that rapidly and accurately predict fluoroqu

270 Despite the advancement of rapid molecular diagnostics, the use of plate cultures inoculated from s

271 Culture-independent diagnostics, the use of sepsis prediction scores, judici

272 istance, and should incorporate rapid fungal diagnostics, therapeutic drug monitoring, and clinical i

273 nd progression in cancer is key to advancing diagnostics, therapeutics and treatment.

274 al reactants, biochemical analytics, medical diagnostics, therapeutics, and nano-bio separations.

275 proaches lend themselves to patient-specific diagnostics, therapeutics, and tissue regeneration.

276 l efforts have been initiated to develop new diagnostics, therapeutics, vaccines, and vector control

277 multifactorial nature and lack of effective diagnostics/therapeutics.

278 and limitations associated with traditional diagnostics/therapeutics.

279 To address the constraints on current diagnostics, this study developed an optoelectrokinetic

280 We implement both spectroscopic and acoustic diagnostics to characterize the properties of uranium pl

281 ew paradigm for the use of molecular genetic diagnostics to guide targeted therapies.

282 full vaccine coverage, access to affordable diagnostics to identify HBV-infected individuals, and to

283 tings, suggesting their utility as candidate diagnostics to predict drug response or to design tactic

284 d XDR-TB in Belarus and will enable improved diagnostics, treatment protocols, and prognostic decisio

285 In contrast to sputum diagnostics, urine Xpert and urine-lipoarabinomannan (LA

286 ave been conventionally assessed in clinical diagnostics using cytogenetic or microarray testing.

287 e pathobiology of cancer and other diseases, diagnostics using in vivo liquid biopsy, and drug delive

288 INTRODUCTION: Component-resolved diagnostics using specific IgE to 2 S albumins has shown

289 Singleplex allergy diagnostics using the alpha-Gal analytes CTX and Bos d T

290 should stimulate similar research themes for diagnostics, vaccines, biological targets and immune res

291 vaccine development, antiviral development, diagnostics, vector competence, and disease pathogenesis

292 natural and recombinant oleosins for allergy diagnostics was investigated by basophil activation test

293 f proteins could benefit other areas such as diagnostics, water treatment, biotechnology and therapeu

294 ustrate the use of this direct PCR method in diagnostics, we amplify human genomic DNA sequences from

295 d in concert with clinical history and other diagnostics where conventional biomarkers indicative of

296 Immunoassays are not widely used in clinical diagnostics, which is mainly due to the limited availabi

297 optical imaging designs that permit on-site diagnostics with a cost-effective mobile-phone-based mul

298 edicines and nanoprobes for chemotherapy and diagnostics with an emphasis on in vivo applications.

299 l be useful in high-throughput point-of-care diagnostics with its minimizing size, light weight, low

300 d without CF, demonstrating convenient sweat diagnostics with reliable detection of cystic fibrosis.